QUALITY MEASURE: FOLLOW-UP CARE FOR CHILDREN STARTING ADHD THERAPY - EDUCATIONAL INTERVENTION
Mailing conducted May 2015 – November 2015

Background:

The Children's Health Insurance Program Reauthorization Act of 2009 (CHIPRA) established the Pediatric Quality Measures Program (PQMP), an initiative funded by the Agency for Healthcare Research and Quality (AHRQ) and the Centers for Medicare & Medicaid Services (CMS) to support the development of new quality measures for use in the Medicaid and CHIP. One measure in the current Child Core Set is “Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder Medication.” At the February 2015 meeting of the DUR Board, recommended that MS-DUR conduct an educational intervention targeting exceptions to this quality measure.

Each month, beneficiaries under the age of 21 were identified who had a prescription filled for a new start on a stimulant used for the treatment of ADHD. Medical claims were examined for these beneficiaries to determine whether a follow-up office visit occurred within 45 days of the initial medication fill.

MAILING

Exception monitoring was run for the ADHD Follow-Up Care Measure each month. Providers were prioritized for mailings each month based on the number of beneficiaries with exceptions. Providers were only contacted once every three months. The following number of providers received letters each month.

<table>
<thead>
<tr>
<th>Month</th>
<th># of Providers Contacted</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 2015</td>
<td>100</td>
</tr>
<tr>
<td>June 2015</td>
<td>43</td>
</tr>
<tr>
<td>October 2015</td>
<td>48</td>
</tr>
<tr>
<td>November 2015</td>
<td>114</td>
</tr>
</tbody>
</table>
Dear Dr. MD_NAME,

The Mississippi Division of Medicaid (DOM) is committed to improving the quality of care provided to Mississippi Medicaid beneficiaries. DOM’s Drug Utilization Review or DUR Board, comprised of twelve physicians and pharmacists from around the state, has recommended several initiatives addressing quality issues regarding the treatment of children with mental health illnesses. This letter is being sent as part of our initiative regarding appropriate follow up care when children begin stimulants for attention deficit/hyperactivity disorder (ADHD).

THE GOAL
The Children’s Health Insurance Program Reauthorization Act of 2009 established the Pediatric Quality Measures Program. This is an initiative funded by the Agency for Healthcare Research and Quality (AHRQ) and the Centers for Medicare & Medicaid Services (CMS) to support the development of new quality measures for use in Medicaid and the Children Health Insurance Program (CHIP). One measure in the current Child Core Set is the percentage of children initiating treatment with a stimulant for ADHD who had a follow-up visit within 30 days of starting therapy. A recent analysis of Mississippi Medicaid found that of the children beginning stimulant therapy only 59.3% had a follow-up visit within 30 days. The Mississippi rate is slightly above the national average reported in the 2014 CMS Annual Report but is far from ideal. It is recognized that appropriate management can occur without a claim for a follow up visit. However, this percentage should be much higher.

WHAT WE ASK OF YOU?
Analysis of Medicaid children (fee-for-service and coordinated care) during the last year showed that you initiated stimulant therapy for (MD_#PTS) children and (MD_%) had a claim for a follow-up visit within 30 days of filling the prescription. The American Academy of Pediatrics recommends that follow-up appointments should be made at least monthly until a child's mental and behavioral symptoms have been stabilized. When initiating treatment with stimulants, we encourage you to do monthly follow-ups until a stable treatment plan has been developed.

We recognize the challenges of diagnosing and establishing a stable treatment of ADHD. The Center for the Advancement of Youth (CAY) at the University of Mississippi Medical Center is working with DOM to provide coordinated care for youngsters with behavioral or developmental issues and to assist community physicians in diagnosing and developing treatment plans for children with ADHD and other behavioral problems. Please feel free to contact CAY to determine how they might help you provide effective coordinated care for children in your practice with behavioral problems. You can reach CAY by phone at their physician-to-physician number 866-862-3627 or by visiting their website http://www.ummchealth.com/cay/.

Sincerely,

Benjamin F. Banahan, III, Ph.D.      Judith P. Clark, R.Ph, B.S. Pharmacy
Project Director               Director, Office of Pharmacy
MS-DUR                Division of Medicaid